Pituitary Tumor Clinical Trial
Official title:
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas
Verified date | October 2017 |
Source | Huashan Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Growth hormone secreting pituitary adenomas(GHomas) produce excessive GH, stimulating excessive insulin like growth factor 1(IGF-1) synthesis in the liver, thus causing multiple systemic complications. The life expectancy of patients with untreated GHomas is shortened by ten years. The treatment goal of GHomas is to shrink the tumor volume and normalize GH and IGF-1. Under current treatment, only 50-70% of patients get remission. Rosiglitazone is a widely used oral antidiabetic medicine. The investigator's preliminary data showed that rosiglitazone decreased the synthesis of GH and IGF-1 in rat pituitary tumor cells GH3 and hepatocytes respectively. The investigator plan to investigate the efficacy of rosiglitazone in the treatment of patients with GHomas who have not been alleviated by other therapies.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | December 31, 2018 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Patients with GHomas confirmed by surgery - Patients who did not get biochemical remission: GH nadir after oral glucose tolerance test(OGTT)>1.0ug/L or IGF-1 exceeds age matched normal range Exclusion Criteria: - Patients who were allergic to rosiglitazone - Patients with liver or kidney dysfunction, respiratory failure - Patients with heart failure - Patients with edema - Patients with severe hyperlipidemia - Patients with osteoporosis or a history of non traumatic fractures - Patients with pregnancy and lactation - Patients who had received radiation therapy within 3 years - Patients who had participated in other clinical trials within 3 months - Patients with other neoplastic diseases - Patients with mental and neurological disorders - Patients with other conditions which were believed not appropriate to take part in the clinical trial |
Country | Name | City | State |
---|---|---|---|
China | Huashan Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Zhaoyun Zhang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Growth hormone(GH) | the decrease of growth hormone(GH) | 6 months | |
Primary | insulin like factor 1(IGF-1) | the decrease of insulin like factor 1(IGF-1) | 6 months | |
Primary | tumor volume | the change of tumor volume | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04529356 -
The TMS Treatment for Postoperative Headache in GH Tumor
|
N/A | |
Completed |
NCT03363126 -
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
|
N/A | |
Completed |
NCT04212793 -
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
|
Phase 1 | |
Terminated |
NCT04106531 -
Validation of a Quality of Life Metric "Prolac-10"
|
||
Recruiting |
NCT03719781 -
Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
|
||
Recruiting |
NCT01556230 -
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
|
||
Recruiting |
NCT03132259 -
Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach
|
Phase 4 | |
Recruiting |
NCT01368133 -
The Observational Study of Growth Hormone-secreting Pituitary Tumors
|
N/A | |
Withdrawn |
NCT04863339 -
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
|
Phase 2 | |
Terminated |
NCT00646308 -
Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas
|
N/A | |
Recruiting |
NCT00852501 -
Characterization of Receptors in Non-functioning Pituitary Macroadenomas
|
Phase 4 | |
Completed |
NCT03465423 -
Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
|
||
Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
Recruiting |
NCT05139277 -
Evaluation of the CONVIVO System
|
N/A | |
Active, not recruiting |
NCT03636568 -
Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)
|
N/A | |
Completed |
NCT02813044 -
Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor
|
N/A | |
Recruiting |
NCT03973450 -
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
|
||
Active, not recruiting |
NCT04042753 -
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
|
Phase 2 | |
Recruiting |
NCT04018963 -
The Impact of Endoscopic Pituitary Surgery on Nasal Function
|
||
Not yet recruiting |
NCT04938401 -
Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection
|